Drugs

Papers
(The H4-Index of Drugs is 58. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression463
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments452
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema339
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments324
Eftrenonacog Alfa: A Review in Haemophilia B231
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”197
Teclistamab: First Approval170
New Therapies on the Horizon for Primary Biliary Cholangitis149
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using147
Spesolimab for the Treatment of Generalized Pustular Psoriasis131
Bimekizumab for the Treatment of Psoriasis129
Targeting DNA Damage Response Deficiency in Thoracic Cancers129
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations126
Senaparib: First Approval120
Vorasidenib: First Approval115
Epcoritamab: First Approval114
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences110
Aprocitentan: First Approval108
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine107
Cosibelimab: First Approval107
Lenacapavir: First Approval101
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies96
Androgenetic Alopecia: Therapy Update96
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure96
Acoltremon: First Approval95
QT Prolongation and Risk of Death with the Use of Methadone for Chronic Cancer and Noncancer Pain: Myths or Reality?94
Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial94
Olipudase Alfa: First Approval90
Ivarmacitinib Sulfate: First Approval86
Atogepant: First Approval85
Drugs in Development to Manage Acute Pain85
Repotrectinib: First Approval84
Danicopan: First Approval83
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer83
Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis83
Finerenone: First Approval83
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids81
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection79
Delgocitinib 20 mg/g Cream: A Review in Chronic Hand Eczema77
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?76
Cancer Pain Treatment Strategies in Patients with Cancer75
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?75
Olverembatinib: First Approval75
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification74
Mosunetuzumab: First Approval71
Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections70
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology69
Correction to: Tapinarof Cream 1%: First Approval68
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes68
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough67
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis66
Situational Prevention of Migraine Attacks: Can Early Treatment Change the Conversation?65
Correction to: Prevention and Treatment of Monkeypox64
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer64
Managing Burning Mouth Syndrome: Current and Future Directions61
Pozelimab: First Approval61
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options60
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned60
The Place of Cannabinoids in the Treatment of Gynecological Pain58
0.056109189987183